drugset / Trial / NCT06563934
Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the additional efficacy and safety of oral enterobacterial capsules in patients with intermediate and advanced liver cancer and treated with tyrosine kinase inhibitors (TKIs) combined with immunotherapy.
Timeline
- Start
- 2024-08-30
- Primary completion
- 2026-05-20
- Completion
- 2026-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enterobacterium capsules | Unknown | 300 mg | Oral |
| Background | Lenvatinib | Small molecule | 8 mg | Oral |
| Background | Lenvatinib | Small molecule | 12 mg | Oral |